PMC:7534795 / 76129-76677
Annnotations
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T462 | 18-23 | Chemical | denotes | PUFAs | http://purl.obolibrary.org/obo/CHEBI_26208 |
| T463 | 47-52 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T464 | 63-98 | Chemical | denotes | specialized pro-resolving mediators | http://purl.obolibrary.org/obo/CHEBI_140399 |
| T465 | 100-104 | Chemical | denotes | SPMs | http://purl.obolibrary.org/obo/CHEBI_140399 |
| T466 | 120-129 | Chemical | denotes | resolvins | http://purl.obolibrary.org/obo/CHEBI_132120 |
| T467 | 131-168 | Chemical | denotes | resolution phase interaction products | http://purl.obolibrary.org/obo/CHEBI_132120 |
| T468 | 189-192 | Chemical | denotes | EPA | http://purl.obolibrary.org/obo/CHEBI_28364 |
| T469 | 204-208 | Chemical | denotes | RvE1 | http://purl.obolibrary.org/obo/CHEBI_81559 |
| T470 | 216-219 | Chemical | denotes | DHA | http://purl.obolibrary.org/obo/CHEBI_16016|http://purl.obolibrary.org/obo/CHEBI_28125|http://purl.obolibrary.org/obo/CHEBI_28689|http://purl.obolibrary.org/obo/CHEBI_36005 |
| T474 | 231-235 | Chemical | denotes | RvD1 | http://purl.obolibrary.org/obo/CHEBI_81564 |
| T475 | 288-291 | Chemical | denotes | DHA | http://purl.obolibrary.org/obo/CHEBI_16016|http://purl.obolibrary.org/obo/CHEBI_28125|http://purl.obolibrary.org/obo/CHEBI_28689|http://purl.obolibrary.org/obo/CHEBI_36005 |
| T479 | 418-429 | Chemical | denotes | metabolites | http://purl.obolibrary.org/obo/CHEBI_25212 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T153 | 0-10 | http://purl.obolibrary.org/obo/GO_0008152 | denotes | Metabolism |
| T154 | 399-408 | http://purl.obolibrary.org/obo/GO_0009058 | denotes | synthesis |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T526 | 0-348 | Sentence | denotes | Metabolism of n-3 PUFAs also generates another group of highly specialized pro-resolving mediators (SPMs) which include resolvins ‘resolution phase interaction products’ produced from both EPA (E-series, RvE1-2) and DHA (D-series, RvD1-6) as well as protectins and maresins produced from DHA (Serhan et al., 2002; Serhan, Chiang, & Van Dyke, 2008). |
| T527 | 349-548 | Sentence | denotes | Both the COX and LOX pathways are involved in the synthesis of these metabolites with distinct epimers being produced in the presence and absence of aspirin (Mas, Croft, Zahra, Barden, & Mori, 2012). |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 33031856-12391014-84038993 | 308-312 | 12391014 | denotes | 2002 |
| 33031856-22912397-84038994 | 542-546 | 22912397 | denotes | 2012 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2189 | 14-23 | Chemical | denotes | n-3 PUFAs | MESH:D015525 |
| 2190 | 189-192 | Chemical | denotes | EPA | MESH:D015118 |
| 2191 | 216-219 | Chemical | denotes | DHA | MESH:D004281 |
| 2192 | 265-273 | Chemical | denotes | maresins | |
| 2193 | 288-291 | Chemical | denotes | DHA | MESH:D004281 |
| 2194 | 498-505 | Chemical | denotes | aspirin | MESH:D001241 |
| 2195 | 204-210 | CellLine | denotes | RvE1-2 | CVCL:1045 |